Fractyl Health, Inc. (GUTS) Stock Price & Analysis
Fractyl Health, Inc. (GUTS) fell 0.88% to USD 0.66 as of June 10, 2026 at 00:27 UTC, according to Nexqual real-time market data.
GUTS last closed at USD 0.67; the session ranged USD 0.66–0.7 on volume of 1,188,903 shares. Market capitalization is $105.36M, with a 52-week range of USD 0.38–2.9 (NGM). Source: Nexqual, June 10, 2026 at 00:27 UTC.
Key Statistics (as of June 10, 2026 at 00:27 UTC)
| Price | USD 0.66 |
|---|---|
| Change | ▼ 0.88% (down) |
| Previous Close | USD 0.67 |
| Open | USD 0.67 |
| Day Range | USD 0.66 – 0.7 |
| 52-Week Range | USD 0.38 – 2.9 |
| Volume | 1,188,903 shares |
| Market Cap | $105.36M |
| Exchange | NGM |
Technical Analysis (GUTS)
Nexqual's technical model rates GUTS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.17 (neutral) |
| vs SMA50 | Below (USD 0.68) |
| MACD | -0 (negative) |
Analyst Ratings (GUTS)
Wall Street analysts rate GUTS "Strong Buy" based on 5 analysts, with a mean price target of USD 5.24 (range USD 2–8), per Nexqual as of June 10, 2026 at 00:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 5.24 |
| High Target | USD 8 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (GUTS)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.07 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.71 vs est -0.32 ▼ miss |
| 2025-06-30 | USD -0.57 vs est -0.36 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financials & Fundamentals (GUTS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -778.33% |
| Debt / Equity | 284.5 |
| Current Ratio | 4.28 |
| Total Cash | $63.17M |
| Total Debt | $60.82M |
| Free Cash Flow | $-50.59M |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financial Health Score (GUTS)
Nexqual rates Fractyl Health, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:27 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $63M cash vs $61M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$88M |
| Efficiency | Critical — ROE -778%, ROA -63.6% |
Ownership (GUTS)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +52.47% |
| Shares Outstanding | 158.65M |
| Float | 143.45M |
| Short % of Float | +1.63% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Leadership (GUTS)
Fractyl Health, Inc. is led by Harith Rajagopalan (age 48), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 00:27 UTC.
| Co-Founder, CEO & Director | Harith Rajagopalan (age 48) |
|---|---|
| Co-Founder, Chief Product Officer & President | Jay D. Caplan BSEE (age 63) |
| CFO & Treasurer | Lara Smith Weber (age 50) |
| Senior Vice President of Regulatory, Quality & Clinical | Jon Fitzgerald |
| Senior Vice President of Market Access & Commercial Strategy | Mike Zumdahl |
Major Backers & Investors (GUTS)
Notable institutional backers of Fractyl Health, Inc. include Nantahala Capital Management, LLC, 683 Capital Management LLC, Pale Fire Capital SE, according to Nexqual as of June 10, 2026 at 00:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 8.42% |
| 683 Capital Management LLC | 4.24% |
| Pale Fire Capital SE | 3.73% |
| Catalio Capital Management, LP | 3.46% |
| General Catalyst Group Management, LLC | 3.08% |
| Deer Management Co. LLC | 3.01% |
| Maverick Capital Ltd. | 2.51% |
| Woodline Partners LP | 1.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.98% |
| BlackRock | 1.55% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
From Fractyl Health, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
- It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
- The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
- Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | USD 21.15 | ▲ 15.83% |
| KYTX | Kyverna Therapeutics, Inc. | USD 7.85 | ▲ 5.09% |
| PEPG | PepGen Inc. | USD 1.38 | ▼ 2.13% |
| IVVD | Invivyd, Inc. | USD 0.99 | ▼ 3.88% |
| AVBP | ArriVent BioPharma, Inc. | USD 30.55 | ▲ 0.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:27 UTC. This page is informational and not investment advice.